Clinical Trials Logo

Adrenoleukodystrophy clinical trials

View clinical trials related to Adrenoleukodystrophy.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03196765 Withdrawn - Clinical trials for X-Linked Adrenoleukodystrophy

Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy

Start date: August 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II, open label dose escalation study of multiple dose levels of NV1205 with a long-term treatment phase.

NCT ID: NCT02948062 Withdrawn - Clinical trials for Adrenoleukodystrophy

Early Diagnosis Of Childhood Cerebral ALD

Start date: November 2018
Phase:
Study type: Observational

The goal of this single institution study is to evaluate boys with adrenoleukodystrophy (ALD) diagnosed early in life, and to prospectively monitor them to determine parameters that will facilitate earlier detection of the childhood cerebral form of the disease. These at-risk subjects will be assessed yearly through travel to the University of Minnesota, where plasma and cerebral spinal fluid (CSF) biomarker studies, MRI based imaging and neuropsychological assessments will be performed at the University of Minnesota Masonic Children's Hospital and Clinics. The MRI and lumbar puncture to obtain CSF will be obtained under sedation. In addition, at intervening 6 months intervals information will be obtained remotely, including surveys and MRI's in their home location. Also at that time blood samples will be obtained locally and shipped to the University of Minnesota for study. There is no therapeutic intent in this study.

NCT ID: NCT02410239 Withdrawn - Clinical trials for Cerebral Adrenoleukodystrophy

MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)

Start date: June 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) of mesenchymal stem cells (IT-MSC) in patients with active, advanced cerebral adrenoleukodystrophy (cALD).

NCT ID: NCT01787578 Withdrawn - Clinical trials for X-Linked Adrenoleukodystrophy

Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)

Start date: April 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerance, pharmacokinetics, and pharmacodynamics of sobetirome, a selective thyroid hormone analog, in adult male X-ALD patients.